Tag: Sutro Biopharma
Sutro’ STRO-002 Receives FDA Fast Track Designation for Patients with Advanced...
The U.S. Food and Drug Administration (FDA) has granted Fast Track designation for STRO-002. The investigational drug, being developed by Sutro Biopharma, is a...
First Patient Dosed in the Dose-Expansion Study of STRO-002 in Patients...
A first patient has been dosed in the dose-expansion cohort of the Phase I study with STRO-002, a folate receptor alpha (FolRα) targeting antibody-drug...
Preclinical Data Suggests Synergy between STRO-002 and Immune Checkpoint Inhibitors, Resulting...
Data presented at the 2020 American Association for Cancer Research (AACR) Virtual Annual Meeting II from June 22-24, 2020 of Sutro Biopharma's folate receptor...
AACR 2020: Phase I Clinical Trial with STRO-002 Shows Encouraging...
Updated interim data regarding safety and anti-tumor activity results in heavily pre-treated patients with ovarian cancer from an on-going Phase I dose-escalation phase clinical...
SutroVax Closes U.S. $ 110 million Series D financing to Advance...
SutroVax, a next-generation vaccine company, has closed a $110 million Series D preferred stock financing, co-led by new investors RA Capital Management and Janus...
James Panek Joins Sutro Biopharma’s Board of Directors
James P. Panek, an independent consultant since 2011, providing technical and strategic insights to companies around the world, has joined Sutro Biopharma's Board of...
Encouraging Preliminary Clinical Data in Ongoing Phase I Study for STRO-002...
Initial safety data of STRO-002 shows potent anti-tumor activity in preclinical endometrial cancer patient-derived xenograft (PDX) models were presented at the AACR-NCI-EORTC.
FRα is overexpressed...
Sutro Biopharma to Receive Milestone Payment from Merck KGaA for Bispecific...
Sutro Biopharma has achieved a milestone under its collaboration and license agreement with the healthcare division of Merck KGaA, Darmstadt, Germany, in the United...
Sutro Biopharma Appoints Former Biogen Idec Executive Connie Matsui as Board...
Sutro Biopharma confirmed that the company has appointed Ms. Connie L. Matsui, retired Executive Vice President of Biogen Idec, as Chair of the company's...
A New Generation of Precisely Engineered CD74-Targeting ADCs Receive Orphan Drug...
The U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for STRO-001 for the treatment of multiple myeloma (MM).
In the United States,...
